^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Excerpt:
...Patients ≥ 18 years of age with histologically, and radiographically confirmed non-metastatic ER-positive (defined as ≥30% of positive cells) and HER2-positive (defined as overexpression by immunohistochemistry (3+) or 2+ and positive by defined by fluorescence or dual in situ hybridization.) breast cancer with minimal tumor size over 2 cm (≥T2 lesion) to receive neoadjuvant chemotherapy recommended by the treating physician 2....
Trial ID:
Source:
Title:
228P - Pathologic response to neoadjuvant antiher2 therapy in HER2 equivocal overexpression with FISH amplification
Published date:
09/14/2020
Excerpt:
A serie of 71 early or locally advanced breast cancer patients with HER2 equivocal overexpression and FISH amplification who received neoadjuvant treatment with chemotherapy and antiHER2 drugs...Patients with equivocal HER2 overexpression and FISH amplification have an overall pCR of only 28.8%. More than 70% have ER positive, and the proportion of pCR is only 17.6%. However, the subgroup with ER negative and high expression of HER2 / CEP17 ratio achieves a percentage of pCR that reaches up to 80%.
